Redeye provides its initial take on MedCap’s Q3 2025 report, which came in broadly above our estimates. Continued outperformance by business areas Assistive Tech and MedTech fuelled this quarter’s top-line beat. While Specialty Pharma sales undershot our projection, its margin recovery continued during Q3 2025. Lastly, organic growth topped our estimate against decent references.
LÄS MER